The frequency of BRCA2 reversion varies across tumour types, reaching approximately 40% in prostate cancer,86 10.3% in HGSOC,87 60% in metastatic breast cancer (mBC)88 and 15–25% in OC progressing after therapy.89 Here, BRCA2 is linked to neoplasm.